Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

DIAI PHARMA : revenue, balance sheet and financial ratios

DIAI PHARMA is a French company founded 7 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in MARSEILLE (13001), this company of category PME shows in 2022 a net income positive of 41 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - DIAI PHARMA (SIREN 840121966)
Indicator 2022 2021 2020 2019
Revenue N/C N/C N/C N/C
Net income 40 586 € 0 € 0 € 0 €
EBITDA -923 € N/C N/C N/C
Net margin N/C N/C N/C N/C

Revenue and income statement

In 2022, DIAI PHARMA generates positive net income of 41 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

EBITDA (2022) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-923 €

EBIT (2022) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-923 €

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

40 586 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 31%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 8%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

31.313%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

8.298%

Repayment capacity (2022) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Solvency indicators evolution
DIAI PHARMA

Sector positioning

Debt ratio
31.31 2022
2020
2021
2022
Q1: 0.04
Med: 14.14
Q3: 118.39
Average -20 pts over 3 years

In 2022, the debt ratio of DIAI PHARMA (31.31) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
8.3% 2022
2020
2021
2022
Q1: 18.05%
Med: 62.02%
Q3: 91.75%
Average

In 2022, the financial autonomy of DIAI PHARMA (8.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.0 years 2022
2022
Q1: -0.0 years
Med: 0.04 years
Q3: 3.93 years
Good

In 2022, the repayment capacity of DIAI PHARMA (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 112.21. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

112.21

Interest coverage (2022) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-893.174

Liquidity indicators evolution
DIAI PHARMA

Sector positioning

Liquidity ratio
112.21 2022
2020
2021
2022
Q1: 118.61
Med: 637.87
Q3: 4243.78
Average

In 2022, the liquidity ratio of DIAI PHARMA (112.21) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-893.17x 2022
2022
Q1: -75.2x
Med: -1.06x
Q3: 0.0x
Average

In 2022, the interest coverage of DIAI PHARMA (-893.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positioning of DIAI PHARMA in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (23 transactions). This range of 305 370€ to 944 402€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2022
Indicative
305k€ 578k€ 944k€
578 641 € Range: 305 370€ - 944 402€
NAF 5 année 2022
How is this estimate calculated?

This estimate is based on the analysis of 23 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare DIAI PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about DIAI PHARMA

What is the revenue of DIAI PHARMA ?

The revenue of DIAI PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is DIAI PHARMA profitable?

Yes, DIAI PHARMA generated a net profit of 41 k€ in 2022.

Where is the headquarters of DIAI PHARMA ?

The headquarters of DIAI PHARMA is located in MARSEILLE (13001), in the department Bouches-du-Rhone.

Where to find the tax return of DIAI PHARMA ?

The tax return of DIAI PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does DIAI PHARMA operate?

DIAI PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.